Autologous adipose‐derived stem cells therapy in COPD treatment: a case report

Here, we describe the clinical course of a patient with chronic obstructive pulmonary disease treated with autologous adipose‐derived stem cell therapy. In September 2019, our patient was admitted to Bach Mai Hospital. His post‐bronchodilator forced expiratory volume in 1 sec (FEV(1)) was 21% and FE...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Thuy Thanh, Phan, Phuong Thu, Nguyen, Binh Huy, Vu, Trang T. Thu, Pham, Phuong Cam, Van Vu, Giap, Nguyen, Khanh Ba, Vu, Trung Thanh, Vu, Luu Dang, Ngo, Chau Quy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080283/
https://www.ncbi.nlm.nih.gov/pubmed/33959296
http://dx.doi.org/10.1002/rcr2.748
Descripción
Sumario:Here, we describe the clinical course of a patient with chronic obstructive pulmonary disease treated with autologous adipose‐derived stem cell therapy. In September 2019, our patient was admitted to Bach Mai Hospital. His post‐bronchodilator forced expiratory volume in 1 sec (FEV(1)) was 21% and FEV(1)/forced vital capacity (FVC) was 40%. He had suffered from two exacerbations of chronic obstructive pulmonary disease (COPD) in the previous year. He received treatment with autologous stem cells from adipose tissue. Follow‐up indicated that autologous stem cells from adipose tissue was a safe treatment and improved the patient's dyspnoea and quality of life.

Ejemplares similares